Treatment Switches, Patterns, and Outcomes in Adult and Pediatric Patients Undergoing Kidney Transplantation Between 2000 and 2019: A Retrospective United States Claims Database Study
Transplantation Proceedings · 2024
DOI: 10.1016/j.transproceed.2024.05.040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation Proceedings, 2024. Verfasst von Yvonne Geissbühler und 7 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharma AG, Basel, Switzerland. Electronic address: yvonne.geissbuehler@novartis.com. Hauptthemen laut MEDLINE: Kidney Transplantation, Immunosuppressive Agents, Databases, Factual, Graft Survival. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis.
Abstract (Originalsprache)
BACKGROUND: Immunosuppressive regimens are imperative for improving patient and graft survival following kidney transplantation in patients with kidney failure. However, real-world evidence regarding treatments and outcomes in these patients is scarce. We sought to describe the treatment switches (assessed by line of treatment [LOT]), patterns, and outcomes in patients who underwent kidney transplantation in the United States. METHODS: This retrospective cohort study used claims data from the Optum Research Database in the United States. Adult and pediatric patients undergoing a kidney transplantation between January 1, 2000, and June 30, 2019, who had ≥1 year of baseline and follow-up visits and continuous enrollment in the Optum Research Database, were included. RESULTS: Data from 7159 patients (6833, adult; 326, pediatric) were included. The mean age for adult and pediatric patients was 51.4 ± 12.8 years and 10.4 ± 5.1 years, respectively. The mean number of LOTs in patients with ≥1 LOT (n = 7004) was 4.1 ± 2.6 LOTs. Tacrolimus, antiproliferative agents, and prednisone were the most frequently prescribed immunosuppressants. No strong correlations were identified between switching from LOT1 to LOT2 and potential predictors of treatment switches. The proportion of patients who did not experience graft loss gradually decreased between month 3 and month 120 (72%-36%), driven by return to dialysis (66%-18%). A slower decrease was observed for graft rejection (98%-84%), retransplantation (98%-93%), and graft removal (98%-92%). CONCLUSIONS: We described treatment switches, patterns, and outcomes in patients who underwent kidney transplantation in the United States. Future analytical studies are needed to test hypotheses derived from these observations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Novartis Pharma AG, Basel, Switzerland. Electronic address: yvonne.geissbuehler@novartis.com.
- Optum, Eden Prairie, Minnesota, United States.
- Novartis Pharma AG, Basel, Switzerland.
- Novartis Pharma AG, Basel, Switzerland; Pfizer AG, Zurich, Switzerland.
Förderung
- Novartis
Zitieren
APA
Geissbühler, Y., Johnson, J. C., Gharbi, H., Aubrun, E., Kuessner, D., Smolskis, J. M., Barcelos, G., & Prieto, L. (2024). Treatment Switches, Patterns, and Outcomes in Adult and Pediatric Patients Undergoing Kidney Transplantation Between 2000 and 2019: A Retrospective United States Claims Database Study. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2024.05.040
Vancouver
Geissbühler Y, Johnson JC, Gharbi H, Aubrun E, Kuessner D, Smolskis JM, et al. Treatment Switches, Patterns, and Outcomes in Adult and Pediatric Patients Undergoing Kidney Transplantation Between 2000 and 2019: A Retrospective United States Claims Database Study. Transplantation Proceedings. 2024. doi:10.1016/j.transproceed.2024.05.040
BibTeX
@article{Geissbhler2024,
author = {Geissbühler, Yvonne and Johnson, Jonathan C and Gharbi, Hakam and Aubrun, Elodie and Kuessner, Daniel and Smolskis, John M and Barcelos, Giovanna and Prieto, Luis},
title = {Treatment Switches, Patterns, and Outcomes in Adult and Pediatric Patients Undergoing Kidney Transplantation Between 2000 and 2019: A Retrospective United States Claims Database Study},
journal = {Transplantation Proceedings},
year = {2024},
doi = {10.1016/j.transproceed.2024.05.040}
}
EUVIMED